Abstract 61P
Background
Natural killer (NK) cells may be particularly suited to cancer therapy. However, the heterogeneity of NK cell populations poses challenges in isolating highly functional subpopulations for therapeutic applications. This study presents a novel microfluidic platform that can select NK cells with enhanced avidity, aiming to improve the precision and efficacy of NK cell-based immunotherapies.
Methods
We used a microfluidics device that uses fluid shear stress to sort and isolate and sort NK cells based on their avidities to the target cells. Briefly, we sterilized our chip and coated it with fibronectin overnight and cultured lung cancer (A549) and ovarian cancer (SKOV3) cells for 24 hours until they achieved a monolayer. We then introduced NK cells on top of the monolayer and left these two types of cells to interact under static condition for 10 minutes. Using syringe pump, we applied fluid flow to induce shear ranging from 0.5Pa to 19.8 Pa in order to isolate the NK cells after each flow. To explore if avidity correlated with cytotoxicity, we cultured monolayer of A549 on our chip then introduced two types of NK cells: treated NK cells (adNK) and NK cells isolated from peripheral blood (cbNK). We followed the same protocol as described above to determine the NK cell type with high avidity.
Results
Our results show that at least 4.5 % and 4% cbNK cells remained attached to SKOV3 cells and A549 respectively after exposure to shear as high as 19.8 Pa. This avidity profile was different for adNK cells on A549. 30% of and NK cells remained attached to A549 cells after 19.8 Pa shear. This result also matched the cytotoxicity profile of adNK cells compared to that of cbNk cells for A549 cells.
Conclusions
In this study we used a novel method to sort and isolate NK cells based on their avidity to its target cancer cells. Although this device has been used to isolate and sort T cell population before, to our knowledge, for the first time we showed that NK cells can be isolated using their avidity to target cells. In addition, the higher avidity adNk cell aligned with its high cytotoxicity suggesting that selecting NK cells based on avidity may lead to selection of potent NK cells.
Legal entity responsible for the study
Imperial College London.
Funding
Imperial College London, Department of Bioengineering Imperial College London, Department of Life Sciences.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
46P - Immunoprofiling of Peripheral Blood Cells as a Potential Predictor of Immune-Related Toxicity of PD-1 Inhibitors
Presenter: Jan Podhorec
Session: Poster Display
47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer
Presenter: Zihan Zhou
Session: Poster Display
51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results
Presenter: Laura Ridolfi
Session: Poster Display
52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.
Presenter: Sumei Chen
Session: Poster Display
53P - Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer
Presenter: Nicholas Brown
Session: Poster Display
55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
Presenter: wei zhang
Session: Poster Display
56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells
Presenter: yue wang
Session: Poster Display
57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Presenter: Liangping Li
Session: Poster Display
59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform
Presenter: silvia Scaglione
Session: Poster Display